Latest News
News
Doctors hesitated to embrace biosimilar infliximab in first 2 years
Adoption of biosimilar infliximab was initially slow, but more widely used in new patients.
Conference Coverage
Clinicians address psoriatic disease risk in the era of COVID-19
Studies suggest psoriatic disease doesn’t much impact the risk of contracting COVID-19 or experiencing worse outcomes from psoriatic disease, but...
News
FDA approves Tremfya (guselkumab) for psoriatic arthritis
The FDA’s approval marks the second indication for guselkumab, which was first approved for adults with plaque psoriasis in 2017.
Conference Coverage
PASDAS beats DAS28 in measuring psoriatic arthritis treat-to-target success
Fewer psoriatic arthritis patients who met low disease activity threshold according to the Psoriatic Arthritis Disease Activity Score (PASDAS) had...
Conference Coverage
Entheseal lesions, bone density linked with incident PsA in psoriasis patients
Metacarpal entheseal lesions and low entheseal bone density in patients with psoriasis each linked with increased incident psoriatic arthritis.
Conference Coverage
TNF inhibitor plus methotrexate surpassed methotrexate monotherapy in PsA
Adding a tumor necrosis factor inhibitor to methotrexate tripled attainment of minimal disease activity, compared with intensified methotrexate...
News
Biologics yield low rates of skin clearance in real-world psoriasis study
“Real world evidence provided by registries is only beginning to emerge.”
Conference Coverage
Biologics better solo than with methotrexate in psoriatic arthritis
Ustekinumab or a tumor necrosis factor inhibitor are better used alone than with methotrexate in the treatment of psoriatic arthritis.
News
Financial incentives affect the adoption of biosimilars
Adoption of infliximab biosimilars proceeded more slowly at an academic medical center than at a neighboring VAMC, where financial incentives to...
News
Genome study examines heritability of psoriatic disease subtypes
Cutaneous psoriasis shows a greater contribution from genetic variants than does psoriatic arthritis or psoriasis vulgaris.